浩欧博2025年度归母净利润2341.81万元 同比下降36.37%

Core Viewpoint - Haobo (688656.SH) reported a decline in both revenue and net profit for the fiscal year 2025, indicating challenges in the macro market environment and increased operational costs [1] Financial Performance - The company achieved operating revenue of 398.40 million yuan, a decrease of 0.98% compared to the same period last year [1] - The net profit attributable to the parent company was 23.42 million yuan, down 36.37% year-on-year [1] Operational Challenges - The overall sales scale slightly declined due to the impact of the macro market environment and related policy adjustments, affecting financial indicators such as revenue and net profit [1] - Increased depreciation expenses from the expansion of automated instrument deployment contributed to a rise in total costs [1] - The new building from fundraising projects has led to an increase in depreciation within fixed costs compared to the previous year [1] Marketing and Investment - The company intensified marketing efforts for the desensitization drug Otuoke, resulting in higher promotional and clinical registration expenses [1]